@DaveARicks Love the $LLY hand already with medicines that work on diseases today and preserve healthspans tomorrow: GLP-1 family; orexin; psychedelics. Robotic wet labs can fill in more of our knowledge gaps about “state aliasing” in pathophysiology, and when to match the tx to timing.
@emollick This is absolutely true, especially in biology where artificial silos between psychiatry and neurology; oncology and immunology; cardiovascular and infectious disease (for example) rule. AI can connect not just dots but separate constellations.
@DrSamuelBHume@moremyspeed Dementia isn’t irrelevant—same gene. DYRK1A doesn’t just degrade cyclin D1, it also phosphorylates tau and primes amyloidogenic APP processing, which is why AD pathology is near-universal in DS by the 40s… And Alzheimer’s & cancer are inversely related generally.
@EricTopol@CellCellPress Interesting: plasma and CSF GFAP track two distinct astrocyte states — plasma is an early, amyloid-specific signal (Pereira 2021, cited), CSF correlates with microglial markers and doesn’t dissociate the same way (Benedet 2021). One green line in Fig 2 hides two biologies.
@DrSamuelBHume Wonder if GLP-1s modulate IL-11. I only see data on classical cytokines. But the hepatic fibrosis data point to a possible impact (as do maybe the Ozempic baby anecdotes).
@matthewherper Fascinating that Regev flags AI’s biggest risk as narcissism. Doesn’t that mirror our own very-human biases that kept us from innovating in Alzheimer’s, told us KRAS was undruggable (!), and laughed at Folkman’s theories about VEGF before Genentech changed the world of cancer?
@AnthropicAI Interpretability can bring insights to human biology. Ablating the J-space breaks the ability to bridge gaps, while immediate associations remain intact. This is the same split that makes delayed recall the earliest marker of dementia. Could inspire new early dx tests.
@AmandaAskell Very true, and very challenging for patients (and also for doctors because frivolous lawsuits are absolutely an occupational hazard). That’s why it’s so imperative to free Fable to think beyond the classical medical silos and form a more integrated map of health and disease.
@samuel_stanton_ THIS will be interesting. But even more interesting will be the white spaces you see. Science has a culture and the thinking becomes ingrained, which could be a blocker to wild and new ideas. Chasing amyloid is one major example; dismissing angiogenesis in cancer is too.
@pineurosci This seems counterintuitive since psychedelics are often described as “opening” the brain, but what’s actually happening is they’re gating what reaches the DMN while shifting the directional balance from bottom-up toward top-down control. Explains utility in PTSD and autism.
@AmandaAskell@ImmunoFever This is, unfortunately, a frequent lived experience especially for women. It’s also true that a lot of people suffer from doing “their own research” and using ineffective quack treatments. Just like powerful AI, powerful medicine needs a balance of access and guardrails.
@IasonGabriel@GoogleDeepMind Fascinating paper and great frame with the waves! I wonder if multi-agenct coordination will end up being harder to solve than intelligence (CooperBench coordination challenges.)
@IdoAizenbud This week’s @ShorterLab preprint makes your finding architecturally beautiful: axonal mito lack mtDNA and don’t produce ATP; dendritic mito do. NMDA computation and OXPHOS power are co-localized in dendrites. The axon has neither. The brain solved the von Neumann bottleneck.
@GrantHBrennerMD@dspetro TMS cascading into different spheres is two plasticity dimensions at once. Treat the circuit rigidity (OCD) and the structural depletion (MDD) starts to move. I wonder whether a single intervention can do enough of both, or whether this is where psychedelics come in.
@ImmunoFever Wow! Perhaps the same evolutionary logic as RBCs: strip the machinery that pollutes. RBCs don’t burn their own O₂. Axonal mito don’t generate ROS along their own transmission line. Glycolysis does the work. Dirty energy stays in the soma. The axon stays clean — by design.
@mgdurrant@parmita@Abhinavsns Thank you! One comment: limiting to institutions reinforces the status quo; hopefully independent researchers will be able to access soon (with appropriate guardrails).
@NatureMedicine Interesting! Oligo_1 appears in TD2 — the earliest transition, before significant tau accumulation.
Myelin isn’t just a bystander. It may be loading microglia with lipid before the plaques fully form.
This shows when the switch flips. Is the oligodendrocyte who’s flipping it?